Instructions for DERMAZINE (Silver sulfadiazine) 50 gr cream
Dermazin cream is a drug with antibacterial action for external use.
Antimicrobial drug for external use, sulfonamide.
When applied to the burn surface, silver sulfadiazine decomposes, slowly and continuously releasing silver and sulfonamide ions, which inhibits the growth and reproduction of bacterial cells.
Dermazin has a wide spectrum of antibacterial activity, including virtually all types of microbes that cause infection of burns and other wounds on the skin surface (including Pseudomonas aeruginosa, Escherichia coli, Proteus spp., Staphylococcus spp., Streptococcus spp., Klebsiella spp., Enterobacter spp.), As well as yeasts (Candida albicans) and some strains of the herpes virus.
Silver sulfadiazine penetrates into necrotic tissue and exudate.
Data on the pharmacokinetics of Dermazin are not provided.
DERMAZINE Indications for use:
Dermazin cream is used in the treatment and prevention of burn infections (including before autodermoplasty); treatment and prevention of infection of trophic ulcers, wounds.
Mode of application:
Dermazin can be applied with or without bandages. The product is intended for use on the skin only.
After surgical treatment of the burn surface, the cream is applied on it with a layer 2-4 mm thick.
The drug should be applied 1-2 times / day.
Treatment should be continued until the wound surface is completely healed.
The method of application of the cream is the same for the treatment of burns and trophic ulcers. Dressings should be changed daily.
Side effects DERMAZINE:
Local reactions: rarely - burning sensation, itching.
On the part of the hematopoietic system: in some cases, the development of transient leukopenia (mainly a decrease in the number of neutrophils) was noted in patients treated with silver sulfadiazine. The maximum decrease in the level of leukocytes is observed 2-4 days after the start of treatment. Then their level is normalized within 2-3 days, while the continuation of treatment with silver sulfathiazine does not affect the process of restoring the number of leukocytes.
There are separate reports on the development of skin necrosis, erythema multiforme, skin pigmentation disorders, interstitial nephritis.
The degree of absorption of silver sulfadiazine depends on the size of the burn surface and the degree of tissue damage.
In rare cases, it is possible to develop any side reactions characteristic of sulfonamides: hematopoiesis disorders (including agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia), skin and allergic reactions (including Stevens-Johnson syndrome and exfoliative dermatitis), dyspeptic symptoms, hepatitis, hepatocellular necrosis, reactions from the central nervous system, toxic nephrosis.
Contraindications to the use of Dermazin cream are: children's age up to 2 months; premature newborns; period of childbirth; hypersensitivity to the components of the drug; hypersensitivity to sulfonamides.
Dermazin should not be used during pregnancy, unless the potential life-saving benefit of use outweighs the potential harm to the fetus. The use of sulfonamides increases the risk of developing hyperbilirubinemia, therefore, Dermazin should not be prescribed, especially in the third trimester of pregnancy and during childbirth. The exception is cases when the potential benefit for saving the patient's life outweighs the existing risk to the fetus.
It is not known whether silver sulfadiazine is excreted in human breast milk. However, other sulfonamides are found in milk. In addition, all sulfonamides increase the risk of hyperbilirubinemia. In connection with the possibility of the development of serious side effects in an infant when using sulfonamides in a nursing mother, if it is necessary to use the drug during lactation, the question of stopping breastfeeding should be decided, taking into account the degree of importance of treatment for the mother.
Interaction with other medicinal products:
Silver sulfadiazine can inactivate enzymatic preparations for wound cleansing when used simultaneously.
It is noted that with the simultaneous use of cimetidine, the risk of developing leukopenia increases.